We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals

30 hedge funds and large institutions have $80.6M invested in Xenon Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

151% more capital invested

Capital invested by funds: $32M → $80.6M (+$48.5M)

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

43% more funds holding

Funds holding: 2130 (+9)

Holders
30
Holders Change
+9
Holders Change %
+42.86%
% of All Funds
0.8%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
9
Increased
8
Reduced
5
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$25.2M +$10.3M +1,333,333 +75%
Capital World Investors
2
Capital World Investors
California
$8.34M
O
3
OrbiMed
New York
$8.1M +$7.72M +1,000,000 New
PA
4
Perceptive Advisors
New York
$6.18M +$2.55M +330,000 +76%
TCM
5
Tekla Capital Management
Massachusetts
$5.67M +$5.41M +700,000 New
DCM
6
DAFNA Capital Management
California
$4.16M +$2.32M +300,000 +140%
IPC
7
Invesco Private Capital
New York
$3.34M -$185K -23,905 -5%
OM
8
Opaleye Management
Massachusetts
$3.32M
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
$2.98M -$194K -25,173 -6%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$2.9M
GTC
11
Ghost Tree Capital
New York
$2.63M +$2.51M +325,000 New
HCMT
12
Highland Capital Management (Texas)
Texas
$2.02M +$1.93M +250,000 New
SFM
13
Sphera Funds Management
Israel
$1.85M +$1.76M +228,029 New
NHAS
14
Novo Holdings A/S
Denmark
$1.03M
Renaissance Technologies
15
Renaissance Technologies
New York
$779K +$368K +47,700 +98%
State of New Jersey Common Pension Fund D
16
State of New Jersey Common Pension Fund D
New Jersey
$527K
WMSA
17
Weiss Multi-Strategy Advisers
New York
$255K -$6.95K -900 -3%
Deutsche Bank
18
Deutsche Bank
Germany
$232K +$194K +25,102 +688%
MIM
19
Monashee Investment Management
Massachusetts
$203K
LWIC
20
Leith Wheeler Investment Counsel
British Columbia, Canada
$171K -$13.9K -1,794 -10%
SC
21
Scotia Capital
Ontario, Canada
$169K +$161K +20,820 New
NSEDCP
22
NJ State Employees Deferred Compensation Plan
New Jersey
$162K
KPF
23
K2 Principal Fund
Ontario, Canada
$122K +$116K +15,000 New
M&T Bank
24
M&T Bank
New York
$115K +$110K +14,251 New
Bank of Montreal
25
Bank of Montreal
Ontario, Canada
$58K

XENE Hedge Fund Activity: Q3 2016 in Review

30 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2016, worth a combined $80.6M — up 151% from $32M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new XENE positions and 0 closed out — a net gain of 9 holders — while 8 added to existing stakes and 5 trimmed.

The largest buyer was BVF Inc, adding an estimated $10.3M. The largest seller was Royal Bank of Canada, cutting an estimated $194K.

  • 30 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2016, up from 21 in Q2 2016.
  • Funds reported $80.6M of Xenon Pharmaceuticals stock for Q3 2016, up 151% quarter-over-quarter.
  • 9 funds opened new Xenon Pharmaceuticals positions in Q3 2016 and 0 closed out, a net change of +9 holders.
  • The largest Xenon Pharmaceuticals buyer in Q3 2016 was BVF Inc, an estimated $10.3M added.
  • The largest Xenon Pharmaceuticals seller in Q3 2016 was Royal Bank of Canada, an estimated $194K sold.

Based on aggregated 13F filings for Q3 2016.